(NASDAQ: AVTE) Aerovate Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 40.36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.8%.
Aerovate Therapeutics's revenue in 2023 is $0.On average, 1 Wall Street analysts forecast AVTE's revenue for 2026 to be $903,498,281, with the lowest AVTE revenue forecast at $903,498,281, and the highest AVTE revenue forecast at $903,498,281. On average, 2 Wall Street analysts forecast AVTE's revenue for 2027 to be $3,177,105,446, with the lowest AVTE revenue forecast at $2,338,958,239, and the highest AVTE revenue forecast at $4,015,277,258.
In 2028, AVTE is forecast to generate $7,966,138,434 in revenue, with the lowest revenue forecast at $4,005,213,783 and the highest revenue forecast at $11,927,063,086.